UY33326A - INSULIN-SIRNA CONJUGATES - Google Patents

INSULIN-SIRNA CONJUGATES

Info

Publication number
UY33326A
UY33326A UY0001033326A UY33326A UY33326A UY 33326 A UY33326 A UY 33326A UY 0001033326 A UY0001033326 A UY 0001033326A UY 33326 A UY33326 A UY 33326A UY 33326 A UY33326 A UY 33326A
Authority
UY
Uruguay
Prior art keywords
relates
specifically
insulin
present
methods
Prior art date
Application number
UY0001033326A
Other languages
Spanish (es)
Inventor
Werner Prof Dr Kramer
Bodo Dr Brunner
Marcus Hermann Korn
David William Dr Will
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY33326A publication Critical patent/UY33326A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Esta invención se refiere de forma general a compuestos terapéuticos y métodos útiles para tratar a enfermedades en seres humanos. Más concretamente, la presente invención se refiere a métodos y reactivos útiles para tratar a seres humanos que padecen enfermedades metabólicas. Más concretamente, la presente invención se refiere a conjugados covalentes de insulina y análogos con derivados de ácidos nucleicos que son capaces de modular la expresión de genes. Además, esta invención se refiere al uso de dichas insulinas conjugadas para el tratamiento de enfermedades metabólicas, incluyendo la diabetes mellitus.This invention generally relates to therapeutic compounds and methods useful for treating diseases in humans. More specifically, the present invention relates to methods and reagents useful for treating humans suffering from metabolic diseases. More specifically, the present invention relates to covalent insulin conjugates and analogs with nucleic acid derivatives that are capable of modulating gene expression. In addition, this invention relates to the use of said conjugated insulins for the treatment of metabolic diseases, including diabetes mellitus.

UY0001033326A 2010-04-14 2011-04-12 INSULIN-SIRNA CONJUGATES UY33326A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305388 2010-04-14

Publications (1)

Publication Number Publication Date
UY33326A true UY33326A (en) 2011-12-01

Family

ID=42633135

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033326A UY33326A (en) 2010-04-14 2011-04-12 INSULIN-SIRNA CONJUGATES

Country Status (4)

Country Link
AR (1) AR080884A1 (en)
TW (1) TW201141513A (en)
UY (1) UY33326A (en)
WO (1) WO2011128374A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939557B1 (en) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 Combination of an insulin and a GLP-1 agonist
RU2537239C2 (en) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Pharmaceutical composition containing agonist glp-1, insulin and methionine
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN103179978A (en) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (en) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Combination medicine used for blood glucose control in patients with type 2 diabetes
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
EP2983697B1 (en) 2013-04-03 2018-10-31 Sanofi Treatment of diabetes mellitus by long acting formulations of insulins
NZ733670A (en) 2014-12-12 2021-12-24 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. Chiral phosphoramidite auxiliaries and methods of their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (en) 1986-07-21 1986-07-21 Novo Industri As NOVEL PEPTIDES
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
WO1988006599A1 (en) 1987-02-25 1988-09-07 Novo Industri A/S Novel insulin derivatives
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
WO1995007931A1 (en) 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
US20060019913A1 (en) 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
JP2006506961A (en) 2002-05-23 2006-03-02 セプティア， インコーポレイテッド Regulation of PTP1B signal transduction by RNA interference
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
AU2004253471B2 (en) * 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1843790A2 (en) 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
EP1907419B1 (en) 2005-07-08 2011-01-26 Biocon Limited Preparation of insulin conjugates
EP1934252B1 (en) 2005-10-13 2015-06-24 Biocon Limited Process for the preparation of insulin conjugates.
EP1942943A2 (en) 2005-11-04 2008-07-16 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
CA2678646A1 (en) 2007-03-05 2008-09-12 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery

Also Published As

Publication number Publication date
TW201141513A (en) 2011-12-01
AR080884A1 (en) 2012-05-16
WO2011128374A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
UY33326A (en) INSULIN-SIRNA CONJUGATES
CY1123010T1 (en) SMALL MOLECULE TRIAL GENE INCIPULATION FROM NORMAL AND TUMOR CELLS AS ANTICANCER THERAPY
CY1120685T1 (en) RETINOID-LIPOSOMES TO STRENGTHEN HSP47 EXPRESSION REGULATION
UY32177A (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
BR112013027119A2 (en) new ligand-drug conjugates (adcs) and their use
BR112012032579A2 (en) "diabetes therapy"
UY32237A (en) ARILO COMPOUNDS WITH HETEROCICLICAL SUBSTITUTES AND THEIR USE
PA8740901A1 (en) ORGANIC COMPOUNDS
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
BR112012031163A2 (en) Combination therapy methods for treatment of proliferative diseases
ECSP13012668A (en) 1-BENCILCICLOALQUILCARBOXÍLICOS ACIDS SUBSTITUTED AND ITS USE
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
GT201200313A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
ECSP13013068A (en) HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE2
UY32030A (en) "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
AR083715A1 (en) COMPOSITIONS AND METHODS FOR THE SELECTIVE DISTRIBUTION OF MOLECULES OF OLIGONUCLEOTIDES TO SPECIFIC TYPES OF NEURONES
UY28757A1 (en) SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
UY31543A1 (en) SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
CL2008000198A1 (en) COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF SICK DISEASES AS TYPE 2 DIABETES, LIPID DISORDER, OBESITY AND ATEROSCLEROSIS.
NZ595189A (en) Combination therapy with thiocolchicine derivatives
BR112013029158A2 (en) lixisenatide as an add-on therapy for basal insulin and type 2 diabetes
EP2582682A4 (en) Methods of treating lung disease
MX2013004406A (en) Treating diabetes melitus using insulin injections administered with varying injection intervals.
BR112012018116A2 (en) "growth hormones with prolonged in vivo efficacy"

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200622